Solmaz Amiri1, Robert Lutz2, M Eugenia Socías3, Michael G McDonell4, John M Roll5, Ofer Amram6. 1. Department of Nutrition and Exercise Physiology, Elson S. Floyd College of Medicine, Washington State University, United States of America. Electronic address: solmaz.amiri@wsu.edu. 2. Department of Nutrition and Exercise Physiology, Elson S. Floyd College of Medicine, Washington State University, United States of America; Spokane Regional Health District, Spokane, WA, United States of America. 3. British Columbia Centre on Substance Use, Vancouver, BC, Canada; Department of Medicine, University of British Columbia, Vancouver, BC, Canada. 4. Program of Excellence in Addiction Research, Washington State University, United States of America; Department of Medical Education and Clinical Sciences, Elson S Floyd College of Medicine, Washington State University, United States of America. 5. Program of Excellence in Addiction Research, Washington State University, United States of America. 6. Department of Nutrition and Exercise Physiology, Elson S. Floyd College of Medicine, Washington State University, United States of America.
Abstract
OBJECTIVE: Adherence to opioid agonist therapy with methadone is associated with improved clinical and community outcomes such as reductions in drug use, criminal behavior, high-risk sexual behavior, and mortality. However, the need for daily attendance for witnessed ingestion may comprise adherence. METHODS: Data for this study were obtained from the Spokane Regional Health District's Treatment Services database. Generalized linear models with negative binomial log link function were used to assess the association between distance to the only state-funded opioid treatment program (OTP) in Spokane County, Washington and the number of missed methadone doses in the first month of treatment. RESULTS: In total, 892 individuals received methadone treatment at this OTP between February 2015 and December 2017. In the adjusted multivariable model, clients who lived more than 10 miles from the OTP were more likely to miss doses compared to individuals who lived within 5 miles of the clinic (IRR = 1.29, 95%CI = 1.03-1.61, p = 0.03). Clients who lived less than 5 miles and between 5 and 10 miles from the OTP were equally likely to miss treatment doses (IRR = 1.02, 95%CI = 0.84-1.23, p = 0.86). CONCLUSIONS: This study found significant positive associations between distance to an OTP and the number of missed doses in the first month of treatment. Findings suggest the need to improve the spatial availability of OTPs to optimize opioid use disorder treatment outcomes.
OBJECTIVE: Adherence to opioid agonist therapy with methadone is associated with improved clinical and community outcomes such as reductions in drug use, criminal behavior, high-risk sexual behavior, and mortality. However, the need for daily attendance for witnessed ingestion may comprise adherence. METHODS: Data for this study were obtained from the Spokane Regional Health District's Treatment Services database. Generalized linear models with negative binomial log link function were used to assess the association between distance to the only state-funded opioid treatment program (OTP) in Spokane County, Washington and the number of missed methadone doses in the first month of treatment. RESULTS: In total, 892 individuals received methadone treatment at this OTP between February 2015 and December 2017. In the adjusted multivariable model, clients who lived more than 10 miles from the OTP were more likely to miss doses compared to individuals who lived within 5 miles of the clinic (IRR = 1.29, 95%CI = 1.03-1.61, p = 0.03). Clients who lived less than 5 miles and between 5 and 10 miles from the OTP were equally likely to miss treatment doses (IRR = 1.02, 95%CI = 0.84-1.23, p = 0.86). CONCLUSIONS: This study found significant positive associations between distance to an OTP and the number of missed doses in the first month of treatment. Findings suggest the need to improve the spatial availability of OTPs to optimize opioid use disorder treatment outcomes.
Authors: Paul J Joudrey; Nicholas Chadi; Payel Roy; Kenneth L Morford; Paxton Bach; Simeon Kimmel; Emily A Wang; Susan L Calcaterra Journal: Drug Alcohol Depend Date: 2020-03-27 Impact factor: 4.492
Authors: Hannah Lf Cooper; David H Cloud; Patricia R Freeman; Monica Fadanelli; Travis Green; Connor Van Meter; Stephanie Beane; Umedjon Ibragimov; April M Young Journal: Int J Drug Policy Date: 2020-03-26
Authors: Deborah W Garnick; Constance M Horgan; Andrea Acevedo; Margaret T Lee; Lee Panas; Grant A Ritter; Kevin Campbell Journal: J Rural Health Date: 2019-05-15 Impact factor: 4.333
Authors: Julie G Salvador; Snehal R Bhatt; Vanessa C Jacobsohn; Larissa A Maley; Rana S Alkhafaji; Heidi Rishel Brakey; Orrin B Myers; Andrew L Sussman Journal: Subst Abus Date: 2020-08-19 Impact factor: 3.716
Authors: Suzan Iloglu; Paul J Joudrey; Emily A Wang; Thomas A Thornhill; Gregg Gonsalves Journal: Drug Alcohol Depend Date: 2021-01-19 Impact factor: 4.492
Authors: Mathew V Kiang; Michael L Barnett; Sarah E Wakeman; Keith Humphreys; Alexander C Tsai Journal: Drug Alcohol Depend Date: 2021-09-24 Impact factor: 4.492
Authors: Li-Tzy Wu; William S John; Eric D Morse; Steve Adkins; Jennifer Pippin; Robert K Brooner; Robert P Schwartz Journal: Addiction Date: 2021-08-16 Impact factor: 6.526